Tag: terms

TORONTO, July 21, 2025 (GLOBE NEWSWIRE) -- Rogers Communications Inc. (“Rogers” or the “Company”) (TSX: RCI.A and RCI.B; NYSE: RCI) announced the pricing terms of its previously announced separate offers (the “Offers”) to purchase for cash up to the Maximum Purchase Amount (as defined in the Offer to Purchase dated July 11, 2025 (the “Offer to Purchase”), as previously amended) of its outstanding notes of the series listed in the table below (collectively, the “Notes”).

A first-of-its-kind solution for women’s arousal - the same active ingredient as in Viagra^® for men - in a proprietary topical formulation demonstrated to work where women need it most

HALF-YEAR REPORT ON THE LIQUIDITY CONTRACT

Los Angeles, California, July 21, 2025 (GLOBE NEWSWIRE) -- As XRP price breaks through $3.55, returning to the spotlight of top cryptocurrencies, a new wave of investors has turned their attention to a fast-rising but little-known project on the XRP ledger: PBK Miner (PBKMiner XRP Mining).
Given XRP's resilience and strong fundamentals, many XRP holders are now looking to PBK Miner, a next-generation XRP mining program driven by artificial intelligence. By launching a 2-day XRP cloud mining contract, the platform provides investors with a flexible and efficient opportunity to accumulate XRP. The program aims to unlock the market's strong demand for low-threshold, high-liquidity XRP investment products.

SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Further to our announcement filed on Form 6-K on November 20, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the affordable treatment of blood and solid cancers, is pleased to announce the successful completion of dose level 1 for its first-in-human Phase I dose-escalation clinical trial (NCT05302037) (“ANGELICA Trial”) for four late stage cancer patients and is scheduled to start dose level 2 of the ANGELICA Trial in third quarter of 2025.

New York, United States, July 21, 2025 (GLOBE NEWSWIRE) -- Graphjet Technology (“Graphjet” or “the Company”) (Nasdaq:GTI), a leading developer of patented technologies to produce graphite and graphene directly from agricultural waste, is proud to announce that the Company is expecting for new equipment and machineries to arrive in Malaysia by the end of the week.